Get the Stockscreener App
2.94
2.80%
0.08
After Hours:
2.94
Ac Immune Sa stock is traded at $2.94, with a volume of 129.25K.
It is up +2.80% in the last 24 hours and up +6.52% over the past month.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$2.86
Open:
$2.92
24h Volume:
129.25K
Relative Volume:
0.40
Market Cap:
$299.21M
Revenue:
$4.28M
Net Income/Loss:
$-84.59M
P/E Ratio:
-3.5017
EPS:
-0.8396
Net Cash Flow:
$-87.79M
1W Performance:
-4.85%
1M Performance:
+6.52%
6M Performance:
+1.03%
1Y Performance:
+48.48%
1-Day Range:
$2.88
$3.08
1-Week Range:
$2.765
$3.20
52-Week Range:
$1.4299
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.94 | 291.07M | 4.28M | -84.59M | -87.79M | -0.8396 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune FY 2025 Results: Eyeing ACI-7104 Catalysts - Seeking Alpha
Trading Recap: Will AC Immune SA stock hit new highs in YEAR2026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) COO Piergiorgio Donati reports shares and long-dated options - Stock Titan
AC Immune shows first brain images of TDP-43 pathology in trial By Investing.com - Investing.com India
AC Immune shows first brain images of TDP-43 pathology in trial - Investing.com Australia
ACIU Unveils Promising Phase 1 Data for TDP-43 PET Imaging - GuruFocus
AC Immune Presents First In vivo Images of Brain TDP-43 - GlobeNewswire
Aug Volume: Does AC Immune SA outperform in volatile markets2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
AC Immune (ACIU) CFO discloses common shares, RSUs and option grants - Stock Titan
AC Immune (NASDAQ: ACIU) director Monika Buetler details initial share and option holdings - Stock Titan
AC Immune (NASDAQ: ACIU) director reports initial Form 3 holdings - Stock Titan
[Form 3] AC Immune SA Initial Statement of Beneficial Ownership - Stock Titan
AC Immune (ACIU) CEO discloses equity and option holdings - Stock Titan
AC Immune (ACIU) director June Carl Howard details share and option stakes - Stock Titan
AC Immune (ACIU) Upgraded to Buy: Here's Why - Yahoo Finance
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? - Yahoo Finance
FY2026 EPS Estimates for AC Immune Lifted by HC Wainwright - MarketBeat
Trend Review: Will AC Immune SA outperform its industry peersWeekly Earnings Recap & Growth Oriented Trading Recommendations - baoquankhu1.vn
ACIU: BTIG Reiterates Buy Rating with $8 Target Price | ACIU Sto - GuruFocus
AC Immune: Advancing Neurology Pipeline and Imminent Alzheimer’s Vaccine Data Support Buy Rating - TipRanks
Jefferies Maintains Buy on ACIU (AC Immune S.A.) March 2026 - Meyka
AC Immune (ACIU) Loss Of CHF 15.9 Million Tests Bullish Profitability Narratives - simplywall.st
Jefferies reiterates AC Immune stock Buy rating on vaccine data By Investing.com - Investing.com Australia
Jefferies reiterates AC Immune stock Buy rating on vaccine data - Investing.com
AC Immune 2025 Financials: Annual Loss of $85M, Q4 Revenue $423KNews and Statistics - IndexBox
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027 - TipRanks
ACIU: Positive interim results for ACI-7104 and strategic focus extend cash runway to Q3 2027 - TradingView
AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year - TipRanks
AC Immune: Fourth Quarter Financial Results Overview - Bitget
AC Immune: Q4 Earnings Snapshot - Barchart
ACIU: Net loss increased to CHF 70.4 million in 2025 as revenue declined and R&D costs remained high - TradingView
AC Immune (NASDAQ: ACIU) posts 2025 loss but flags key 2026 trial milestones - Stock Titan
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
AC Immune (ACIU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
AC Immune SA expected to post a loss of 17 rappen a shareEarnings Preview - TradingView
Risk Report: What is AC Immune SAs book value per shareJuly 2025 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Aug Big Picture: Should I buy AC Immune SA stock nowJuly 2025 Patterns & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for AC Immune SA stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 - GlobeNewswire
Inside a 2026 push to prevent Parkinson’s at AC Immune’s symposium - Stock Titan
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Will AC Immune SA stock hit new highs in YEAR2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) Begins Phase 1 Trial for New Inflammation Treat - GuruFocus
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor - Investing.com Nigeria
AC Immune Doses First Participant in Phase 1 Trial of NLRP3 Inhibitor ACI-19764 - TipRanks
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor By Investing.com - Investing.com South Africa
AC Immune (NASDAQ: ACIU) begins Phase 1 test of NLRP3 inhibitor ACI-19764 - Stock Titan
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor - The Manila Times
Can AC Immune SA deliver consistent EPS growthMarket Volume Report & Community Verified Trade Signals - mfd.ru
ACIU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug EndMonth: Can AC Immune SA deliver consistent EPS growthTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):